Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H10BrClN2O |
Molecular Weight | 349.61 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=C(C=CC=C1)C2=NCC(=O)NC3=C2C=C(Br)C=C3
InChI
InChIKey=CGMJQQJSWIRRRL-UHFFFAOYSA-N
InChI=1S/C15H10BrClN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)
DescriptionCurator's Comment: Description was created based on several sources, including https://extrapharmacy.ru/pdf/Phenazepam.pdf http://www.valentapharm.com/eng/phenazepam/
Curator's Comment: Description was created based on several sources, including https://extrapharmacy.ru/pdf/Phenazepam.pdf http://www.valentapharm.com/eng/phenazepam/
Phenazepam belongs to the 1,4-benzodiazepines, the same family of medicines to which diazepam, oxazepam and temazepam belong. Phenazepam was first synthesized and developed in 1975 in the former Soviet Union where it became one of the most prescribed benzodiazepines since 1978 to treat sleep disorder, anxiety, alcohol use disorder and epilepsy. Phenazepam has not been licensed elsewhere in the world. The actions of phenazepam are mediated by the GABAA-receptor and reversed by the selective benzodiazepine antagonist flumazenil. In vitro, phenazepam and its metabolite 3-hydroxyphenazepam potentiate GABA responses with EC50-values of 6.1 nM and 10.3 nM, respectively, comparable to the value of 13.5 nM for diazepam. In vivo, phenazepam induces pronounced myorelaxation in the rotarod test with an ED50-value of 2.48 (1.65-3.72) mg/kg, and at 10 mg/kg it decreases punished responding in the conflict test (conflict between drinking motivation and painful electrical stimuli). Phenazepam increases the duration of sleep induced by hexanal several fold and is in this respect superior to diazepam. Both phenazepam and 3-hydroxyphenazepam are full GABAA receptor agonists.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2109244 |
6.1 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Fenazepam Approved UseFenazepam is used in various neurotic, neurosis-like, psychopathic, psychopathy-like and other conditions, accompanied by anxiety, fear, increased irritability, stress, mood swings, reactive psychoses, senesthopathic-hypochondriac syndrome (including cases resistant to other anxiolytics), vegetative and sleep disorders, anxiety and mental stress prophylaxis.
As anticonvulsant medication in temporal lobe and myoclonic epilepsy.
Fenazepam is used in neurology for management of hyperkinesis and tic disorders, muscular rigidity, vegetative dysfunction. Launch Date1978 |
|||
Primary | Fenazepam Approved UseFenazepam is used in various neurotic, neurosis-like, psychopathic, psychopathy-like and other conditions, accompanied by anxiety, fear, increased irritability, stress, mood swings, reactive psychoses, senesthopathic-hypochondriac syndrome (including cases resistant to other anxiolytics), vegetative and sleep disorders, anxiety and mental stress prophylaxis.
As anticonvulsant medication in temporal lobe and myoclonic epilepsy.
Fenazepam is used in neurology for management of hyperkinesis and tic disorders, muscular rigidity, vegetative dysfunction. Launch Date1978 |
|||
Primary | Fenazepam Approved UseFenazepam is used in various neurotic, neurosis-like, psychopathic, psychopathy-like and other conditions, accompanied by anxiety, fear, increased irritability, stress, mood swings, reactive psychoses, senesthopathic-hypochondriac syndrome (including cases resistant to other anxiolytics), vegetative and sleep disorders, anxiety and mental stress prophylaxis.
As anticonvulsant medication in temporal lobe and myoclonic epilepsy.
Fenazepam is used in neurology for management of hyperkinesis and tic disorders, muscular rigidity, vegetative dysfunction. Launch Date1978 |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of nicergoline on learning and memory. | 1988 Jul |
|
[Using computer sound cards in electrophysiological data processing]. | 2001 Jan-Feb |
|
[Predicting individual reactions to emotional stress and benzodiazepine tranquilizers]. | 2001 Jan-Feb |
|
[Is it possible to predict individual stress resistance by evaluating low dose benzodiazepine effect in modeled emotional stress]. | 2001 Mar-Apr |
|
Effect of activators and blockers of ligand-regulated ion channels on the activity of the Cl-stimulated Mg2+-ATPase of the plasma membrane fraction from bream (Abramis brama L.) brain. | 2002 Feb |
|
Biokinetics of transdermal 3-hydroxyphenazepam. | 2002 Sep |
|
Psychotropic activity of the antialcohol preparation Proproten-100. | 2003 Jan |
|
Phenazepam in therapeutic and ultralow doses in vitro modulates the content of lipid peroxidation products and acetylcholinesterase activity in membrane fraction from mouse brain. | 2003 Jan |
|
Pharmacological activity of phenazepam and flunitrazepam in ultralow doses. | 2003 Jan |
|
[Pharmacokinetics and efficacy of phenazepam after transdermal and enteral administration in rats]. | 2003 Jan-Feb |
|
[Clinical picture and treatment of agoraphobia with panic disorder]. | 2003 Jun |
|
[Effect of naloxone on the activity of Cl(-)-activated Mg(2+)-ATPase from plasma membrane fraction of the common bream brain (Abramis brama L.) in the presence of GABAa-ergic substances]. | 2003 Mar-Apr |
|
The influence of anticonvulsant and antioxidant drugs on nitric oxide level and lipid peroxidation in the rat brain during penthylenetetrazole-induced epileptiform model seizures. | 2003 May |
|
[The influence of pharmacologically active substances of different classes at ultra low doses on lipid peroxidation in brain cell membranes and activity of acetylcholinesterase in vivo and in vitro]. | 2003 May-Jun |
|
[Effects of psychotropic drugs of different classes injected in super small doses]. | 2003 May-Jun |
|
[Screening method for compounds acting at super low concentrations]. | 2003 May-Jun |
|
[Characteristics of clinical and pharmacological efficacy of tranquilizers and antidepressants in patients with ischemic heart disease and type A behavior]. | 2004 |
|
[Stress-induced alteration of the antiaggressive effect of anxiolytics]. | 2004 Jul-Aug |
|
[Experimental pharmacokinetics of phenazepam during transdermal administration of the therapeutic phenaperkuten system]. | 2004 Mar-Apr |
|
[Methodological bases of early psychosocial rehabilitation of poststroke patients in neurological hospital]. | 2005 |
|
[Preoperative psychopharmacological correction in women with focal breast diseases]. | 2005 May-Jun |
|
[Application of extraction freezing for analysis of 1,4-benzodiazepines in urine]. | 2007 Mar-Apr |
|
Study of bipathic effect of phenazepam. | 2007 Oct |
|
[Predictors of the efficacy of methods for psychocorrection in patients with irritable bowel syndrome and constipation]. | 2008 Sep-Oct |
|
Tenoten in the therapy of patients with moderate cognitive impairment. | 2009 Aug |
|
The use of tenoten and tenoten (pediatric formulation) as a drug for premedication in adults and children during outpatients dentist visit. | 2009 Aug |
|
[Abuse of phenazepam--new phenomenon in Sweden. Benzodiazepine derivative from Russia caused severe intoxication]. | 2009 Feb 18-24 |
|
[Therapeutic effect and pharmacokinetics of transdermal phenazepam preparation in patients with different anxiety disorders]. | 2009 Mar-Apr |
|
β-Polymorph of phenazepam: a powder study. | 2010 Sep 25 |
Patents
Sample Use Guides
Rx dosage: 0.5 mg 2-3 times daily (10 mg daily maximum)
Recreational dose: 0.5 – 2.0 mg (online user states 1 mg phenazepam = 5 mg diazepam in effect)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12949645
In concentrations of 10(-5)-10(-9) and 10(-15)-10(-17) M Phenazepam possessed antioxidant activity in membrane fraction from mouse brain..
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-Phenazepam
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
PHENAZEPAM
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
100000079408
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
3DSB43090Z
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
SUB14828MIG
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
C017928
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
40113
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
51753-57-2
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
C98139
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
DTXSID00199685
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
SALT/SOLVATE (PARENT)